Business Context and Reporting Period
Company: Propanc Biopharma, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 26, 2021
Event: Entry into a Material Definitive Agreement (Securities Purchase Agreement) with Sixth Street Lending, LLC.
Key Financial Metrics and Transaction Details
- Principal Amount: $53,750 (Convertible Promissory Note).
- Net Proceeds: $50,000 (intended for general working capital).
- Transaction Costs: $3,750 paid to Sixth Street for fees and expenses.
- Interest Rate: 8% per annum (payable in cash or shares of common stock).
- Maturity Date: November 26, 2022.
- Conversion Terms: Convertible at the option of Sixth Street starting May 20, 2022. Conversion price is 65% of the Market Price (35% discount).
- Default Penalty: Upon certain events of default, the obligation increases to 150% of the outstanding principal plus accrued interest.
Material Changes and Prepayment Terms
The filing discloses a new debt obligation not present in prior periods. The Note includes a prepayment option with escalating premiums based on the timing of repayment:
- Within 60 days: 110% of face amount + accrued interest.
- 61-90 days: 115% of face amount + accrued interest.
- 91-120 days: 120% of face amount + accrued interest.
- 121-150 days: 125% of face amount + accrued interest.
- 151-180 days: 129% of face amount + accrued interest.
The filing text does not provide comparative financial metrics (revenue, profit, cash flow) for the prior period as this is a transaction-specific report.
Guidance, Risks, and Covenants
Management Commentary: The Company intends to use net proceeds for general working capital purposes. The transaction is expected to close on or about December 2, 2021.
Risks and Contingencies:
- Conversion Cap: Sixth Street is restricted from converting if it would result in beneficial ownership exceeding 4.99% of outstanding shares.
- Default Events: Include failure to issue shares upon conversion (penalty of $1,000/day), insolvency, failure to maintain OTC/Nasdaq/NYSE listing, or failure to comply with SEC reporting requirements.
- Asset Disposition: The Company covenants not to sell substantially all assets without consent, which would render it a "shell company."
- Share Reserve: The Company must reserve at least five times the number of shares issuable upon full conversion.
Investor Verification Checklist
- Verify the closing of the transaction and receipt of the $50,000 net proceeds.
- Monitor the Company's ability to maintain its listing on OTC markets or equivalent exchanges to avoid default.
- Review the Company's cash position to assess the ability to service the 8% interest or convert to equity without excessive dilution.
- Confirm the reservation of sufficient shares to cover the 5x conversion requirement.
- Check for any subsequent filings regarding the prepayment of the Note or acceleration of the debt.